337 related articles for article (PubMed ID: 33012326)
1. Biologics for the Treatment of Allergic Conditions: Eosinophil Disorders.
Olivieri B; Tinazzi E; Caminati M; Lunardi C
Immunol Allergy Clin North Am; 2020 Nov; 40(4):649-665. PubMed ID: 33012326
[TBL] [Abstract][Full Text] [Related]
2. Targeted Anti-IL-5 Therapies and Future Therapeutics for Hypereosinophilic Syndrome and Rare Eosinophilic Conditions.
Harish A; Schwartz SA
Clin Rev Allergy Immunol; 2020 Oct; 59(2):231-247. PubMed ID: 31919743
[TBL] [Abstract][Full Text] [Related]
3. Current and emerging biologic therapies targeting eosinophilic disorders.
Pitlick MM; Li JT; Pongdee T
World Allergy Organ J; 2022 Aug; 15(8):100676. PubMed ID: 35983569
[TBL] [Abstract][Full Text] [Related]
4. Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor.
Molfino NA; Gossage D; Kolbeck R; Parker JM; Geba GP
Clin Exp Allergy; 2012 May; 42(5):712-37. PubMed ID: 22092535
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of interleukin-5 for the treatment of eosinophilic diseases.
Corren J
Discov Med; 2012 Apr; 13(71):305-12. PubMed ID: 22541618
[TBL] [Abstract][Full Text] [Related]
6. The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: Asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis.
Nagase H; Ueki S; Fujieda S
Allergol Int; 2020 Apr; 69(2):178-186. PubMed ID: 32139163
[TBL] [Abstract][Full Text] [Related]
7. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
Hilvering B; Xue L; Pavord ID
Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
[TBL] [Abstract][Full Text] [Related]
8. Current update on eosinophilic lung diseases and anti-IL-5 treatment.
Samitas K; Rådinger M; Bossios A
Recent Pat Antiinfect Drug Discov; 2011 Sep; 6(3):189-205. PubMed ID: 21824072
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs.
Varricchi G; Bagnasco D; Borriello F; Heffler E; Canonica GW
Curr Opin Allergy Clin Immunol; 2016 Apr; 16(2):186-200. PubMed ID: 26859368
[TBL] [Abstract][Full Text] [Related]
10. Benralizumab in the management of rare primary eosinophilic lung diseases.
Griscti Soler D; Bennici A; Brunetto S; Gangemi S; Ricciardi L
Allergy Asthma Proc; 2022 Nov; 43(6):494-500. PubMed ID: 36335418
[No Abstract] [Full Text] [Related]
11. Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels.
Stein ML; Villanueva JM; Buckmeier BK; Yamada Y; Filipovich AH; Assa'ad AH; Rothenberg ME
J Allergy Clin Immunol; 2008 Jun; 121(6):1473-83, 1483.e1-4. PubMed ID: 18410960
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-5 Antagonists Usher in a New Generation of Asthma Therapy.
Giannetti MP; Cardet JC
Curr Allergy Asthma Rep; 2016 Nov; 16(11):80. PubMed ID: 27796795
[TBL] [Abstract][Full Text] [Related]
13. Mepolizumab in the treatment of severe eosinophilic asthma.
Fainardi V; Pisi G; Chetta A
Immunotherapy; 2016; 8(1):27-34. PubMed ID: 26653083
[TBL] [Abstract][Full Text] [Related]
14. Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma.
Roufosse F
Front Med (Lausanne); 2018; 5():49. PubMed ID: 29682504
[TBL] [Abstract][Full Text] [Related]
15. Super-responders to anti-IL-5/anti-IL-5R are characterised by high sputum eosinophil counts at baseline.
Gerday S; Graff S; Moermans C; Guissard F; Paulus V; Henket M; Louis R; Schleich F
Thorax; 2023 Nov; 78(11):1138-1141. PubMed ID: 37657926
[TBL] [Abstract][Full Text] [Related]
16. Eosinophilic respiratory disorders and the impact of biologics.
Bernstein JS; Wechsler ME
Curr Opin Pulm Med; 2023 May; 29(3):202-208. PubMed ID: 36866734
[TBL] [Abstract][Full Text] [Related]
17. Immunological and hematological effects of IL-5(Rα)-targeted therapy: An overview.
Hassani M; Koenderman L
Allergy; 2018 Oct; 73(10):1979-1988. PubMed ID: 29611207
[TBL] [Abstract][Full Text] [Related]
18. Biologics for the Treatment of Allergic Rhinitis, Chronic Rhinosinusitis, and Nasal Polyposis.
Eschenbacher W; Straesser M; Knoeddler A; Li RC; Borish L
Immunol Allergy Clin North Am; 2020 Nov; 40(4):539-547. PubMed ID: 33012318
[TBL] [Abstract][Full Text] [Related]
19. Targeting eosinophils: severe asthma and beyond.
Caminati M; Menzella F; Guidolin L; Senna G
Drugs Context; 2019; 8():212587. PubMed ID: 31391853
[TBL] [Abstract][Full Text] [Related]
20. Biological Modulators in Eosinophilic Diseases.
Sriaroon P; Ballow M
Clin Rev Allergy Immunol; 2016 Apr; 50(2):252-72. PubMed ID: 25129490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]